Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis
about
Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasisDistinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.Autophagy: a new target for nonalcoholic fatty liver disease therapyNew advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseasesHCV derived from sera of HCV-infected patients induces pro-fibrotic effects in human primary fibroblasts by activating GLI2The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stressesDecorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycinRoles of tissue transglutaminase in ethanol-induced inhibition of hepatocyte proliferation and alpha 1-adrenergic signal transduction.Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation.A comprehensive review of immunosuppression used for liver transplantation.Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.Rapamycin is neuroprotective in a rat chronic hypertensive glaucoma model.Inhibitory effects of rapamycin on the different stages of hepatic fibrosisCultivating hepatocytes on printed arrays of HGF and BMP7 to characterize protective effects of these growth factors during in vitro alcohol injury.mTOR inhibitors: an overview.Heparin-binding EGF-like growth factor induces heart interstitial fibrosis via an Akt/mTor/p70s6k pathway.Developing strategies for liver fibrosis treatment.Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy.Effect of imatinib mesylate and rapamycin on the preformed intimal hyperplasia in rat carotid injury model.Liver transplantation for hepatitis C virus related liver diseaseA Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer BiologyMolecular mechanisms of hepatic fibrogenesis.Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy.Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance.Advances in antifibrotic therapy.Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients.mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regenerationThe Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.Autophagy and Crohn's disease: at the crossroads of infection, inflammation, immunity, and cancer.Treatment options for primary sclerosing cholangitis.Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressantsGrowing experience with mTOR inhibitors in pediatric solid organ transplantation.Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue.Selective apoptosis in hepatic stellate cells mediates the antifibrotic effect of phenanthrenes from Dendrobium nobile.Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells.Role for hedgehog signaling in hepatic stellate cell activation and viability.Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway.
P2860
Q24299083-AE822C37-CFD1-4298-870A-297B0B51D314Q24519078-540FB5D9-3FBC-4616-BF85-EF9440814989Q26751326-E6756C88-ED2C-438E-ABC2-3E9074F6C8B4Q27026399-3D2B4B3D-4104-4312-8294-10D9CEAF3286Q27468911-194E5776-17A9-451B-8C50-460BB16951E5Q28240102-A4EFBF92-2514-443F-8442-12A253D8AFF1Q28572913-E9BB7458-6AC4-4E8A-AE57-E3F6012C2E11Q31364539-2959119C-9835-4B90-9214-AFC17EBBD198Q33251433-611E367E-6A03-4323-A01E-49264983188EQ33588984-079FE45B-6958-4753-AA41-E898FE2D06CFQ33602527-1266B7E3-0435-44C4-81B7-09578160E196Q33737181-D5F171E7-C6E2-4CDF-99D7-E3D54B9AE210Q33748844-A4E5FB54-C042-454C-B709-249379A015D8Q33780195-A5A54EF7-0CF9-49C3-89C4-3EB7C8D28291Q33945660-EEC53B39-8C99-4589-BC42-5C32C20996E1Q34302240-A3567656-FE57-4630-9BDE-056C0E28CC47Q34416270-9BB6E229-0327-43AE-8C66-80C10676A8F7Q35001014-70C73EA1-A9A4-4736-9263-30DDB22AD968Q35012339-18305B33-FF15-4932-946E-0D330F0F5E03Q35139482-E0F9D1BD-2EB7-49A9-9B1F-B066EA365402Q36339458-BD2EEC7E-E299-453C-A243-B096A90AFF63Q36743890-0BE99CC7-4499-4F70-9163-D50D6B111E71Q36849062-4FE88B3F-ADDF-4C1A-971A-3220FD124255Q36909237-7E7C64B4-28F8-4657-86F3-E2A79F942E3BQ37001941-6763EF30-6FA9-4743-A526-91FF4A3CE680Q37016775-632D6D8F-4C1D-4553-B46B-D52E073E9E9FQ37155930-BE90C184-C36E-485A-9B5C-0C3C42FB82FAQ37353099-5B8467D2-48A9-4AA8-AC82-1EE7687589F6Q37355472-2D481AB7-C49A-4E33-B99F-6728CE4AA5DAQ37469156-F1BB76FF-8476-4A49-99E7-A32BC5FAB10CQ37639714-B429495C-9845-4878-A74A-641429E38916Q37764367-54BFCB94-194A-4095-84AA-6B8164D5BA3AQ37777156-D879BD24-08F0-4826-9F15-44625D1D6F16Q38011694-B8535BD1-5E3E-4CA0-BCD2-0F073E9D6DFFQ38134146-ADD3FE10-A2AB-4180-994D-A3570B7B3F5FQ38223370-80EA023F-1A99-4003-93C4-05976B0E9946Q39432627-23F6AE77-D6B0-4661-B202-74F325A9EBEBQ39605054-08D2AA14-1E04-48F6-91B5-A9D3163C873CQ40371810-DE6ABA7F-98E9-4515-998B-BE779C74BB92Q40572900-D3DF4765-8316-4DC9-8C8C-898657877575
P2860
Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@ast
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@en
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@nl
type
label
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@ast
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@en
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@nl
prefLabel
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@ast
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@en
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@nl
P2093
P3181
P1433
P1476
Rapamycin inhibits hepatic ste ...... n vivo model of liver fibrosis
@en
P2093
P304
P3181
P356
10.1016/S0016-5085(99)70406-3
P407
P577
1999-11-01T00:00:00Z